Anti-insulin-like growth factor 1 receptor (IGF-1R) antibodies and method of use thereof to treat thyroid-associated opthamology
AssigneeSuzhou Pro-heal Pharmaceuticals technology Co., Ltd.
InventorsShuhua Guo, Lin Ma, Peng Zhang
Life of this patent
Estimating the term…
Abstract
The invention provides an antibody that can bind IGF-1R. The antibody is composed of light chain and heavy chain. The light chain and heavy chain variable regions are one of the combinations of SEQ ID NO:2 and SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, SEQ ID NO:12 and SEQ ID No 13, SEQ ID NO:14 and SEQ ID NO:15. The invention also provides nucleic acid molecules encoding the antibody binding IGF-1R, vectors containing the nucleic acid, cells transformed by the vectors, and uses of these nucleic acids, vectors, and cells.
Claims4
An anti-IGF-1R antibody, comprising any one of SEQ ID NO:
- 2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:
- 12, SEQ ID NO:14 as a light chain variable region (VL);
- and any one of SEQ ID NO:
- 3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:
- 11, SEQ ID NO:
- 13, SEQ ID NO:15 as a heavy chain variable region (VH), wherein the VL and VH's combination is one of SEQ ID NO:2 and SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:
- 5, SEQ ID NO:6 and SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9, SEQ ID NO:
- 10 and SEQ ID NO:11, SEQ ID NO:
- 12 and SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:15, wherein the light chain comprises VL and light chain constant region (CL) as SEQ ID NO:16;
- and the heavy chain comprises VH and heavy chain constant region (CH) as SEQ ID NO:17.
Dependencies are inferred from the claim text.